- Home
- CSTL vs CCD Comparison
CSTL vs CCD Comparison
Compare CSTL & CCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- CCD
- Stock Information
- Founded
- CSTL 2007
- CCD 2014
- Country
- CSTL United States
- CCD United States
- Employees
- CSTL N/A
- CCD N/A
- Industry
- CSTL Medical Specialities
- CCD Trusts Except Educational Religious and Charitable
- Sector
- CSTL Health Care
- CCD Finance
- Exchange
- CSTL Nasdaq
- CCD Nasdaq
- Market Cap
- CSTL 661.7M
- CCD 581.7M
- IPO Year
- CSTL 2019
- CCD N/A
- Fundamental
- Price
- CSTL $33.02
- CCD $21.46
- Analyst Decision
- CSTL Strong Buy
- CCD
- Analyst Count
- CSTL 6
- CCD 0
- Target Price
- CSTL $38.67
- CCD N/A
- AVG Volume (30 Days)
- CSTL 421.5K
- CCD 96.1K
- Earning Date
- CSTL 11-03-2025
- CCD 01-01-0001
- Dividend Yield
- CSTL N/A
- CCD 10.61%
- EPS Growth
- CSTL N/A
- CCD N/A
- EPS
- CSTL N/A
- CCD N/A
- Revenue
- CSTL $343,530,000.00
- CCD N/A
- Revenue This Year
- CSTL N/A
- CCD N/A
- Revenue Next Year
- CSTL N/A
- CCD N/A
- P/E Ratio
- CSTL N/A
- CCD N/A
- Revenue Growth
- CSTL 10.15
- CCD N/A
- 52 Week Low
- CSTL $14.59
- CCD $16.93
- 52 Week High
- CSTL $34.64
- CCD $24.68
- Technical
- Relative Strength Index (RSI)
- CSTL 81.56
- CCD 44.43
- Support Level
- CSTL $23.31
- CCD $21.52
- Resistance Level
- CSTL $34.36
- CCD $21.98
- Average True Range (ATR)
- CSTL 1.50
- CCD 0.44
- MACD
- CSTL 1.08
- CCD -0.04
- Stochastic Oscillator
- CSTL 89.19
- CCD 22.76
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About CCD Calamos Dynamic Convertible & Income Fund
Calamos Dynamic Convertible and Income Fund operates as a diversified, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation. It predominantly invests in a portfolio of convertible securities, investment grade and below investment grade bonds, loans, equity-linked notes, and floating rate securities.